CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 137 target
Drug / intervention
PART-trialradiation
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Histopathologically confirmed prostate cancer diagnosis
  • ✓pN1 disease after ePLND
  • ✓No prior prostate cancer treatment
  • ✓Age over 18 years
Key exclusion· 6
  • ✕Recurrent disease status
  • ✕Distant metastases (cM1a, cM1b, or cM1c)
  • ✕Prior radiotherapy precluding WPRT and/or PART
  • ✕Prior malignancy not disease-free >5 years (except basocellular skin epithelioma)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03079323
NCT03079323Phase 2RecruitingUpdate OverdueUpdated 23mo ago · Completion was 16mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

Phase II Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer Using Arc Therapy (IMAT/VMAT)

Universitaire Ziekenhuizen KU Leuven·interventional·Posted Mar 14, 2017·Updated Jul 3, 2024

In Brief

A Phase 2 clinical trial evaluating PART-trial for Prostate Cancer. Currently recruiting, targeting 137 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

Prospective non-randomized phase 2 trial to study the efficacy of additional elective para-aortic RT (PART) in pN1 patients compared to those who were historically treated with adjuvant whole pelvic radiotherapy (WPRT) alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesBelgium
Collaborators--

Timeline

Phase 2RecruitingOverdue
2017201820192020202120222023202420252026
First PostedMar 14, 2017
Enrollment StartFeb 6, 2017
Primary CompletionFeb 1, 2025
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 9.3 years ago

Interventions

PART-trialradiation

Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy